

## SEQUENCE LISTING

<110> LINTNER, KARL  
GABRIELE, DENISE E.

<120> COSMETIC OR DERMOPHARMACEUTICAL COMPOSITIONS  
OF CERAMIDES AND POLYPEPTIDES

<130> SEDERM 3.0-002

<140>  
<141>

<150> FR 03 05707  
<151> 2003-05-12

<160> 13

<170> PatentIn Ver. 3.2

<210> 1  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<220>  
<223> see specification as filed for detailed description of lipid  
group attachments and preferred embodiments

<400> 1  
Val Gly Val Ala Pro Gly  
1 5

<210> 2  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<220>  
<223> see specification as filed for detailed description of lipid  
group attachments and preferred embodiments

<400> 2  
Lys Thr Thr Lys Ser  
1 5

<210> 3  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<220>  
<223> see specification as filed for detailed description of lipid group attachments and preferred embodiments

<400> 3  
Gly Gln Pro Arg  
1

<210> 4  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Formula sequence

<220>  
<221> MOD\_RES  
<222> (1)..(3)  
<223> Variable amino acid or amino acid derivative; this region may encompass 0-3 amino acids; see specification as filed for detailed description of R-group substitutions and preferred embodiments

<220>  
<221> MOD\_RES  
<222> (10)..(12)  
<223> Variable amino acid or amino acid derivative; this region may encompass 0-3 amino acids; see specification as filed for detailed description of R-group substitutions and preferred embodiments

<400> 4  
Xaa Xaa Xaa Val Gly Val Ala Pro Gly Xaa Xaa Xaa  
1 5 10

<210> 5  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<220>  
<223> see specification as filed for detailed description of lipid group attachments and preferred embodiments

<220>  
<221> MOD\_RES  
<222> (5)  
<223> Met or Leu

<400> 5  
Tyr Gly Gly Phe Xaa  
1 5

<210> 6  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<220>  
<223> see specification as filed for detailed description of lipid group attachments and preferred embodiments

<400> 6  
Leu Gly Leu Ala Pro Leu  
1 5

<210> 7  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<220>  
<223> see specification as filed for detailed description of lipid group attachments and preferred embodiments

<400> 7  
Ala Val Gly Val Ala Pro Gly  
1 5

<210> 8  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic

peptide

<220>

<223> see specification as filed for detailed description of lipid group attachments and preferred embodiments

<400> 8

Ala Val Gly Val Ala Pro Gly Leu

1 5

<210> 9

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> see specification as filed for detailed description of preferred embodiments

<400> 9

Leu Gly Val Ala Pro Ala

1 5

<210> 10

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> see specification as filed for detailed description of lipid group attachments and preferred embodiments

<400> 10

Val Gly Leu Gly Pro Gly

1 5

<210> 11

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>  
<223> see specification as filed for detailed description of lipid group attachments and preferred embodiments

<400> 11  
Ile Ala Ile Ala Pro Gly  
1 5

<210> 12  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<220>  
<223> see specification as filed for detailed description of preferred embodiments

<400> 12  
Ile Ala Val Val Gly Ala Pro Gly Ala  
1 5

<210> 13  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<220>  
<223> see specification as filed for detailed description of preferred embodiments

<400> 13  
Ser Val Gly Val Ala Pro Gly  
1 5